國立高雄大學圖資館 |

登入

回首頁

Identification of ASCT2 as the Primary Serine Transporter in Cancer /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Identification of ASCT2 as the Primary Serine Transporter in Cancer /Kelly Conger.
作者:	Conger, Kelly,
面頁冊數:	1 electronic resource (142 pages)
附註:	Source: Dissertations Abstracts International, Volume: 86-01, Section: B.
附註:	Advisors: Frasor, Jonna; Coloff, Jonathan L. Committee members: Hay , Nissim; Er, Emrah; VanderGriend, Donald.
Contained By:	Dissertations Abstracts International86-01B.
標題:	Oncology.
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31496265
ISBN:	9798382953472

Identification of ASCT2 as the Primary Serine Transporter in Cancer /
Conger, Kelly,

Identification of ASCT2 as the Primary Serine Transporter in Cancer /Kelly Conger. - 1 electronic resource (142 pages)

Source: Dissertations Abstracts International, Volume: 86-01, Section: B.

Amino acid metabolism is central to cancer cell's ability to proliferate, evade the immune system, and resist cell death. To acquire amino acids cells can utilize several mechanisms: de novo synthesis of nonessential amino acids, autophagy, macropinocytosis, and uptake of exogenous free amino acids. Recently, the non-essential amino acid serine has gained significant interest for its role in protein, nucleotide, lipid, and antioxidant metabolism. As a key contributor to cancer cell growth, serine metabolism has already been targeted for cancer therapy. Serine synthesis inhibitors have been developed and tested, but fail to account for redundant sources of exogenous serine. Systemic serine depletion has also been investigated as a way to limit the supply of exogenous serine, but may have costly side-effects. Reducing serine uptake by directly inhibiting serine transporters is a targeted approach to depriving cancer cells of a vital nutrient. Unfortunately, serine transporters have not yet been identified. Here, we characterize the amino acid transporter ASCT2 (coded for by the gene SLC1A5) as the dominant serine transporter in cancer cells. ASCT2 has previously been recognized as an important glutamine transporter in cancer, as many tumors are considered "glutamine-addicted". However, we present the first evidence that ASCT2 contributes directly to serine uptake in a range of cancer cell lines. We further show that glutamine and serine compete for uptake by ASCT2, and that serine-auxotrophic luminal breast cancer cells specifically upregulate ASCT2 in response to serine, not glutamine deprivation. Additionally, we find that ASCT2-mediated serine uptake directly effects purine nucleotide biosynthesis and define a novel mechanism of transporter regulation by ERα. Finally, we find that combining genetic ablation of ASCT2 with a serine-free diet led to tumor regression in a xenograft model of luminal breast cancer. The work presented here is the first to define a new role for ASCT2 as a serine transporter in cancer and evaluate ASCT2 as a potential therapeutic target in serine metabolism.

English

ISBN: 9798382953472Subjects--Topical Terms:

195181
Oncology.
Subjects--Index Terms:

Breast cancer

Identification of ASCT2 as the Primary Serine Transporter in Cancer /
LDR:03727nmm a22004813i 4500 001 676368
005 20250420214352.5
006 m o d
007 cr|nu||||||||
008 250901s2024 miu||||||m |||||||eng d
020 $a 9798382953472
035 $a (MiAaPQD)AAI31496265
035 $a (MiAaPQD)0799vireo288Conger
035 $a AAI31496265
040 $a MiAaPQD $b eng $c MiAaPQD $e rda
100 1 $a Conger, Kelly, $e author. $3 990172
245 1 0 $a Identification of ASCT2 as the Primary Serine Transporter in Cancer / $c Kelly Conger.
264 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2024
300 $a 1 electronic resource (142 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 86-01, Section: B.
500 $a Advisors: Frasor, Jonna; Coloff, Jonathan L. Committee members: Hay , Nissim; Er, Emrah; VanderGriend, Donald.
502 $b Ph.D. $c University of Illinois at Chicago $d 2024.
520 $a Amino acid metabolism is central to cancer cell's ability to proliferate, evade the immune system, and resist cell death. To acquire amino acids cells can utilize several mechanisms: de novo synthesis of nonessential amino acids, autophagy, macropinocytosis, and uptake of exogenous free amino acids. Recently, the non-essential amino acid serine has gained significant interest for its role in protein, nucleotide, lipid, and antioxidant metabolism. As a key contributor to cancer cell growth, serine metabolism has already been targeted for cancer therapy. Serine synthesis inhibitors have been developed and tested, but fail to account for redundant sources of exogenous serine. Systemic serine depletion has also been investigated as a way to limit the supply of exogenous serine, but may have costly side-effects. Reducing serine uptake by directly inhibiting serine transporters is a targeted approach to depriving cancer cells of a vital nutrient. Unfortunately, serine transporters have not yet been identified. Here, we characterize the amino acid transporter ASCT2 (coded for by the gene SLC1A5) as the dominant serine transporter in cancer cells. ASCT2 has previously been recognized as an important glutamine transporter in cancer, as many tumors are considered "glutamine-addicted". However, we present the first evidence that ASCT2 contributes directly to serine uptake in a range of cancer cell lines. We further show that glutamine and serine compete for uptake by ASCT2, and that serine-auxotrophic luminal breast cancer cells specifically upregulate ASCT2 in response to serine, not glutamine deprivation. Additionally, we find that ASCT2-mediated serine uptake directly effects purine nucleotide biosynthesis and define a novel mechanism of transporter regulation by ERα. Finally, we find that combining genetic ablation of ASCT2 with a serine-free diet led to tumor regression in a xenograft model of luminal breast cancer. The work presented here is the first to define a new role for ASCT2 as a serine transporter in cancer and evaluate ASCT2 as a potential therapeutic target in serine metabolism.
546 $a English
590 $a School code: 0799
650 4 $a Oncology. $3 195181
650 4 $a Biochemistry. $3 188609
650 4 $a Physiology. $3 192980
650 4 $a Cellular biology. $3 708607
653 $a Breast cancer
653 $a Amino acid
653 $a Metabolism
653 $a Serine
653 $a Tumor
653 $a Glutamine
690 $a 0992
690 $a 0487
690 $a 0379
690 $a 0719
710 2 $a University of Illinois at Chicago. $b Physiology and Biophysics. $e degree granting institution. $3 990173
720 1 $a Frasor, Jonna $e degree supervisor.
720 1 $a Coloff, Jonathan L. $e degree supervisor.
773 0 $t Dissertations Abstracts International $g 86-01B.
790 $a 0799
791 $a Ph.D.
792 $a 2024
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31496265